Circulating Biomarkers for Predicting Cardiovascular Disease Risk; a Systematic Review and Comprehensive Overview of Meta-Analyses

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  van Holten, Thijs C ^a   Waanders, Leonie F ^b   de Groot, Philip G ^a   Vissers, Joost ^c   Hoefer, Imo E ^a   Pasterkamp, Gerard ^a   Prins, Menno W J ^b   Roest, Mark ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b PHILIPS RESEARCH LABORATORIES   (Netherlands)

^c Research and Development Future Diagnostics   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; CREATININE; CYSTATIN C; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN; LIPID; TROPONIN I; TROPONIN T; URIC ACID; VITAMIN D;

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; DISEASE ASSOCIATION; DISEASE MARKER; HEMOSTASIS; HIGH RISK POPULATION; HUMAN; INFLAMMATION; ISCHEMIA; KIDNEY FUNCTION; META ANALYSIS (TOPIC); PROGNOSIS; RISK ASSESSMENT; SYSTEMATIC REVIEW; THROMBOSIS;

BIOLOGICAL MARKERS; HUMANS; PROSPECTIVE STUDIES; RISK; THROMBOSIS;

EID: 84876436135     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0062080     Document Type: Article

References (46)

1. Alwan A, Armstrong T, Bettcher D, Branca F, Chisholm D, et al. (2011) Burden: mortality, morbidity and risk factors. Global Status Report on Noncommunicable Diseases 2010: 9-32.
2. Oxman AD, Cook DJ, Guyatt GH, (1994) Users' guides to the medical literature. VI. How to use an overview. Evidence-Based Medicine Working Group. Jama 272: 1367-1371.
3. Moher D, Liberati A, Tetzlaff J, Altman DG (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 151: 264-269, W264.
4. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, et al. (2009) Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 119: 2408-2416.
5. Danesh J, Lewington S, Thompson SG, Lowe GD, Collins R, et al. (2005) Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. Jama 294: 1799-1809.
6. Shah T, Casas JP, Cooper JA, Tzoulaki I, Sofat R, et al. (2009) Critical appraisal of CRP measurement for the prediction of coronary heart disease events: new data and systematic review of 31 prospective cohorts. Int J Epidemiol 38: 217-231.
7. Thompson A, Danesh J, (2006) Associations between apolipoprotein B, apolipoprotein AI, the apolipoprotein B/AI ratio and coronary heart disease: a literature-based meta-analysis of prospective studies. J Intern Med 259: 481-492.
8. Lewington S, Whitlock G, Clarke R, Sherliker P, Emberson J, et al. (2007) Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet 370: 1829-1839.
9. Grandi NC, Breitling LP, Brenner H, (2010) Vitamin D and cardiovascular disease: systematic review and meta-analysis of prospective studies. Prev Med 51: 228-233.
10. Hemingway H, Philipson P, Chen R, Fitzpatrick NK, Damant J, et al. (2010) Evaluating the quality of research into a single prognostic biomarker: a systematic review and meta-analysis of 83 studies of C-reactive protein in stable coronary artery disease. PLoS Med 7: e1000286.
11. Lee M, Saver JL, Huang WH, Chow J, Chang KH, et al. (2010) Impact of elevated cystatin C level on cardiovascular disease risk in predominantly high cardiovascular risk populations: a meta-analysis. Circ Cardiovasc Qual Outcomes 3: 675-683.
12. Ottani F, Galvani M, Nicolini FA, Ferrini D, Pozzati A, et al. (2000) Elevated cardiac troponin levels predict the risk of adverse outcome in patients with acute coronary syndromes. Am Heart J 140: 917-927.
13. Padayachee L, Rodseth RN, Biccard BM, (2009) A meta-analysis of the utility of C-reactive protein in predicting early, intermediate-term and long term mortality and major adverse cardiac events in vascular surgical patients. Anaesthesia 64: 416-424.
14. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, et al. (2011) Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 79: 1341-1352.
15. Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, et al. (2009) Hyperuricemia and risk of stroke: a systematic review and meta-analysis. Arthritis Rheum 61: 885-892.
16. Libby P, Ridker PM, (1999) Novel inflammatory markers of coronary risk: theory versus practice. Circulation 100: 1148-1150.
17. Ridker PM, (1999) Evaluating novel cardiovascular risk factors: can we better predict heart attacks? Ann Intern Med 130: 933-937.
18. Tousoulis D, Papageorgiou N, Androulakis E, Briasoulis A, Antoniades C, et al. (2011) Fibrinogen and cardiovascular disease: genetics and biomarkers. Blood Rev 25: 239-245.
19. Cushman M, Ballantyne CM, Levy D, Rifai N, Cooper GR, et al. (2009) Inflammation Biomarkers and Cardiovascular Disease Risk. In: Meyers GL, editor. Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke: The National Academy of Clinical Biochemistry. pp. 7-24.
20. Maison P, Mennen L, Sapinho D, Balkau B, Sigalas J, et al. (2002) A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration. Atherosclerosis 160: 155-160.
21. The BIP Study Group (2000) Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 102: 21-27.
22. Tanne D, Benderly M, Goldbourt U, Boyko V, Brunner D, et al. (2001) A prospective study of plasma fibrinogen levels and the risk of stroke among participants in the bezafibrate infarction prevention study. Am J Med 111: 457-463.
23. Siegerink B, Rosendaal FR, Algra A, (2009) Genetic variation in fibrinogen; its relationship to fibrinogen levels and the risk of myocardial infarction and ischemic stroke. J Thromb Haemost 7: 385-390.
24. Elamin MB, Abu Elnour NO, Elamin KB, Fatourechi MM, Alkatib AA, et al. (2011) Vitamin D and cardiovascular outcomes: a systematic review and meta-analysis. J Clin Endocrinol Metab 96: 1931-1942.
25. Wang L, Manson JE, Song Y, Sesso HD, (2010) Systematic review: Vitamin D and calcium supplementation in prevention of cardiovascular events. Ann Intern Med 152: 315-323.
26. Wallace AM, Gibson S, de la Hunty A, Lamberg-Allardt C, Ashwell M, (2010) Measurement of 25-hydroxyvitamin D in the clinical laboratory: current procedures, performance characteristics and limitations. Steroids 75: 477-488.
27. Fassett RG, Venuthurupalli SK, Gobe GC, Coombes JS, Cooper MA, et al. (2011) Biomarkers in chronic kidney disease: a review. Kidney Int 80: 806-821.
28. Taglieri N, Koenig W, Kaski JC, (2009) Cystatin C and cardiovascular risk. Clin Chem 55: 1932-1943.
29. Myers GL (2009) Markers of Renal Function and Cardiovascular Disease Risk. In: Meyers GL, editor. Laboratory Medicine Practice Guidelines Emerging Biomarkers for Primary Prevention of Cardiovascular Disease and Stroke: The National Academy of Clinical Biochemistry. 43-50.
30. Laterza OF, Price CP, Scott MG, (2002) Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 48: 699-707.
31. Coutinho M, Gerstein HC, Wang Y, Yusuf S, (1999) The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 233-240.
32. Santos-Oliveira R, Purdy C, da Silva MP, dos Anjos Carneiro-Leao AM, Machado M, et al. (2011) Haemoglobin A1c levels and subsequent cardiovascular disease in persons without diabetes: a meta-analysis of prospective cohorts. Diabetologia 54: 1327-1334.
33. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, et al. (2004) C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 350: 1387-1397.
34. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, et al. (2007) Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 115: 450-458.
35. Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, et al. (2009) Major lipids, apolipoproteins, and risk of vascular disease. Jama 302: 1993-2000.
36. Whincup PH, Danesh J, Walker M, Lennon L, Thomson A, et al. (2002) von Willebrand factor and coronary heart disease: prospective study and meta-analysis. Eur Heart J 23: 1764-1770.
37. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Bmj 321: 199-204.
38. Rodseth RN, Lurati Buse GA, Bolliger D, Burkhart CS, Cuthbertson BH, et al. (2011) The predictive ability of pre-operative B-type natriuretic peptide in vascular patients for major adverse cardiac events: an individual patient data meta-analysis. J Am Coll Cardiol 58: 522-529.
39. Heidenreich PA, Go A, Melsop KA, Alloggiamento T, McDonald KM, et al. (2000) Prediction of risk for patients with unstable angina. Evid Rep Technol Assess (Summ): 1-3.
40. Fleming SM, Daly KM, (2001) Cardiac troponins in suspected acute coronary syndrome: a meta-analysis of published trials. Cardiology 95: 66-73.
41. Wu AH, Lane PL, (1995) Metaanalysis in clinical chemistry: validation of cardiac troponin T as a marker for ischemic heart diseases. Clin Chem 41: 1228-1233.
42. Olatidoye AG, Wu AH, Feng YJ, Waters D, (1998) Prognostic role of troponin T versus troponin I in unstable angina pectoris for cardiac events with meta-analysis comparing published studies. Am J Cardiol 81: 1405-1410.
43. Heidenreich PA, Alloggiamento T, Melsop K, McDonald KM, Go AS, et al. (2001) The prognostic value of troponin in patients with non-ST elevation acute coronary syndromes: a meta-analysis. J Am Coll Cardiol 38: 478-485.
44. Wu AH, Boden WE, McKay RG, (2002) Long-term follow-up of patients with increased cardiac troponin concentrations following percutaneous coronary intervention. Am J Cardiol 89: 1300-1302.
45. Feldman DN, Kim L, Rene AG, Minutello RM, Bergman G, et al. (2011) Prognostic value of cardiac troponin-I or troponin-T elevation following nonemergent percutaneous coronary intervention: a meta-analysis. Catheter Cardiovasc Interv 77: 1020-1030.
46. Nienhuis MB, Ottervanger JP, Bilo HJ, Dikkeschei BD, Zijlstra F, (2008) Prognostic value of troponin after elective percutaneous coronary intervention: A meta-analysis. Catheter Cardiovasc Interv 71: 318-324.